on Sonnet BioTherapeutics, Inc. (NASDAQ:SONN)
Sonnet BioTherapeutics to Showcase SON-080 Research at AACR 2024
Sonnet BioTherapeutics Holdings, Inc., a pioneering biopharmaceutical firm, has announced its plans to present preclinical data and clinical trial design on SON-080 for treating Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the American Association for Cancer Research (AACR) Annual Meeting 2024. The event is scheduled from April 5-10 in San Diego, California. SON-080, a recombinant human Interleukin-6 (rhIL-6), is aimed at addressing complications arising from chemotherapy.
The presentation, titled "Low dose interleukin-6 (SON-080) for neuropathies: Toxicology and clinical plans," falls under the Pharmacology and Pharmacogenetics session. It's slated for poster display on April 10, 2024, from 9:00 AM to 12:30 PM, providing insights into the therapeutic potential of SON-080 in managing CIPN. Attendees can find the presentation at Poster Section 24, Poster Board Number 22.
R. P.Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Sonnet BioTherapeutics, Inc. news